The following transcript has been edited for clarity:

Welcome to Retinal Physician; I'm Dr. Diana Do. I’m joined today by Dr. Avni Finn from Vanderbilt University. She's going to give us a highlight of her presentation at the American Society of Retinal Specialists (ASRS) meeting. Avni, I know you were discussing tyrosine kinase inhibitors and how they can address that unmet need of the excessive treatment burden we see in anti-VEGF therapy. Tell us some of the highlights of your presentation.

Avni Finn, MD: Sure. Thank you so much for having me. Like you alluded to, our patients with wet macular degeneration, we know require high burden of treatment. They require frequent injections. We know the more frequently we inject them, oftentimes the better their vision and the better their long-term visual prognosis. And so tyrosine kinase inhibitors are an opportunity to really lower that treatment burden for patients. I’m discussing the DAVIO2 data and how EYP-1901 (Duravyu; EyePoint Pharmaceuticals), which is a tyrosine kinase inhibitor, a potent anti-VEGF/pan-VEGF inhibitor that’s made to last about 6 months can help us address that treatment burden. And what we saw in the trial data, an analysis of that trial data is that the patients enrolled in the DAVIO2 trial had a very high treatment burden pretrial, so they were receiving on average, about 10 injections over the year prior to the trial. After they were dosed with either high or low dose EYP-1901, they were able to receive only 1 to 2 supplemental injections over the year following that insertion of the implant.

Diana Do, MD: That's great. I mean, that would be a game changer, because that would help control their disease with fewer injections. That’s a very exciting development and we look forward to future data on the phase 3 clinical trials as they finish enrollment as well. Thank you so much, Avni, we really appreciate your insights. RP